Clinical application of tissue engineered human heart valves using autologous progenitor cells

Circulation

Volumn 114, Issue SUPPL. 1, 2006, Pages

  Cebotari, Serghei ^a   Lichtenberg, Artur ^a   Tudorache, Igor ^a   Hilfiker, Andres ^a   Mertsching, Heike ^a   Leyh, Rainer ^a   Breymann, Thomas ^a   Kallenbach, Klaus ^a   Maniuc, Liviu ^b   Batrinac, Aurel ^b   Repin, Oleg ^b   Maliga, Oxana ^b   Ciubotaru, Anatol ^b   Haverich, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Scientific and Practical Center of Cardiovascular Surgery   (Moldova)

Author keywords

Congenital; Heart defects; Surgery; Valves

Indexed keywords

CD31 ANTIGEN; EDETIC ACID; TRYPSIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADOLESCENT; ALLOGRAFT; ARTICLE; BIOREACTOR; CASE REPORT; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART RIGHT VENTRICLE; HEART VALVE REPLACEMENT; HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONONUCLEAR CELL; MORPHOLOGY; PRIORITY JOURNAL; PULMONARY VALVE INSUFFICIENCY; SCHOOL CHILD; STAINING; STEM CELL; TISSUE ENGINEERING; VALVULAR HEART DISEASE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BIOPROSTHESIS; CELL CULTURE; CHILD; CLINICAL TRIAL; CONGENITAL MALFORMATION; CYTOLOGY; FALLOT TETRALOGY; HEART VALVE PROSTHESIS; INSTRUMENTATION; METHODOLOGY; MONOCYTE; POSTOPERATIVE COMPLICATION; PULMONARY ARTERY; PULMONARY VALVE; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; BIOPROSTHESIS; BIOREACTORS; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MONOCYTES; POSTOPERATIVE COMPLICATIONS; PULMONARY ARTERY; PULMONARY VALVE; PULMONARY VALVE INSUFFICIENCY; TETRALOGY OF FALLOT; TISSUE ENGINEERING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33747204634     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.001065     Document Type: Article

References (25)

1. Ross DN, Somerville J. Correction of pulmonary atresia with a homograft aortic valve. Lancet. 1966;2:1446-1447.
2. Rastelli GC, Wallace RB, Ongley PA. Complete repair of transposition of the great arteries with pulmonary stenosis. A review and report of a case corrected by using a new surgical technique. Circulation. 1969;39:83-95.
3. de Ruijter FT, Weenink I, Hitchcock FJ, Meijboom EJ, Bennink GB. Right ventricular dysfunction and pulmonary valve replacement after correction of tetralogy of Fallot. Ann Thorac Surg. 2002;73:1794-1800.
4. Forbess JM. Conduit selection for right ventricular outflow tract reconstruction: contemporary options and outcomes. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:115-124.
5. Homann M, Haehnel JC, Mendler N, Paek SU, Holper K, Meisner H, Lange R. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. Eur J Cardiothorac Surg. 2000;17:624-630.
6. Hawkins JA, Breinholt JP, Lambert LM, Fuller TC, Profaizer T, McGough EC, Shaddy RE. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg. 2000;119:324-330.
7. Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U, Rieder E, Wolner E. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg. 2003;23:1002-1006.
8. Dearani JA, Danielson GK, Puga FJ, Schaff HV, Warnes CW, Driscoll DJ, Schleck CD, Ilstrup DM. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg. 2003;75:399-410.
9. Vesely I. Heart valve tissue engineering. Circ Res. 2005;97:743-755.
10. Cebotari S, Mertsching H, Kallenbach K, Kostin S, Repin O, Batrinac A, Kleczka C, Ciubotaru A, Haverich A. Construction of autologous human heart valves based on an acellular allograft matrix. Circulation. 2002;106:I63-I68.
11. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
12. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, Berger S, Frommelt MA, Lewis DA, Friedberg DZ, Thomas JP, Jr., Sachdeva R, Litwin SB. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation. 2000;102:III130-135.
13. Miller DC, Stinson EB, Oyer PE, Billingham ME, Pitlick PT, Reitz BA, Jamieson SW, Baumgartner WA, Shumway NE. The durability of porcine xenograft valves and conduits in children. Circulation. 1982;66:I172-I185.
14. Breymann T, Boethig D, Goerg R, Thies WR. The Contegra bovine valved jugular vein conduit for pediatric RVOT reconstruction: 4 years experience with 108 patients. J Card Surg. 2004;19:426-431.
15. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79:1072-1080.
16. Fiddler GI, Gerlis LM, Walker DR, Scott O, Williams GJ. Calcification of glutaraldehyde-preserved porcine and bovine xenograft valves in young children. Ann Thorac Surg. 1983;35:257-261.
17. Sutherland FW, Perry TE, Yu Y, Sherwood MC, Rabkin E, Masuda Y, Garcia GA, McLellan DL, Engelmayr GC, Jr., Sacks MS, Schoen FJ, Mayer JE, Jr. From stem cells to viable autologous semilunar heart valve. Circulation. 2005;111:2783-2791.
18. Rieder E, Seebacher G, Kasimir MT, Eichmair E, Winter B, Dekan B, Wolner E, Simon P, Weigel G. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation. 2005;111:2792-2797.
19. da Costa FD, Dohmen PM, Duarte D, von Glenn C, Lopes SV, Filho HH, da Costa MB, Konertz W. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg. 2005;27:572-578.
20. Lichtenberg A, Tudorache I, Cebotari S, Sturz G, Goerler H, Ringes-Lichtenberg S, Karck M, Brandes G, Hilfiker A, Haverich A. Preclinical testing of tissue engineered heart valves re-endothelialized under simulated physiological conditions Circulation. 2005;112:II-750.
21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
22. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
23. Ward KE, Elkins RC, Overholt ED, Knott-Craig CJ, Razook JD, Lane MM, Gilliland SS. Evaluation of cryopreserved homografts in the right ventricular outflow tract after the Ross procedure: intermediate-term follow up. J Heart Valve Dis. 1997;6:130-133.
24. Chan KC, Fyfe DA, McKay CA, Sade RM, Crawford FA. Right ventricular outflow reconstruction with cryopreserved homografts in pediatric patients: intermediate-term follow-up with serial echocardiographic assessment. J Am Coll Cardiol. 1994;24:483-489.
25. Carr-White GS, Kilner PJ, Hon JK, Rutledge T, Edwards S, Burman ED, Pennell DJ, Yacoub MH. Incidence, location, pathology, and significance of pulmonary homograft stenosis after the Ross operation. Circulation. 2001;104:I16-20.